Home » Clinical Trials » Therapeutic Areas

Therapeutic Areas: Neurology
Disease Category: Memory Problems
Location: United States, FL

Clinical Trial Details

Overview

Research Study Summary

A Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)

Purpose
The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
To Learn more

CW ID: 222915
Date Last Changed: February 3, 2017

Clinical Trial Snapshot

Phase
4
Gender
Both Male and Female
Age
65 to 85 Years
Overall Status
Recruiting
Lead Sponsor
Enzymotec
Facility Type
N/A

Eligibility

Inclusion Criteria:
  1. Age greater than or equal to 65 and less than or equal to 85 years.
  2. Formal education greater than or equal to 10 years.
  3. Male or female with a diagnosis of Mild Cognitive Impairment (MCI) 3. Male or female with a diagnosis of Mild Cognitive Impairment (MCI) as defined by Peterson, according to The following:
    • Clinical Dementia Rating Scale total score (CDR) =0.5, and score of each one of the six categories ("box scores") = 1. 3.2 Mini Mental State Exam > 24 3.3 Verbal Paired-Associated Learning test score according to the following ages: Ages 65-70 less than or equal to 18 Ages 71-85* less than or equal to 17
    • *Eligibility of subjects aged between 70 and 71 (i.e., 70.1) will be evaluated according to 71-85 age group score.
  4. Adequate vision, hearing, and literacy ability to allow for neuropsychological testing.
  5. Able and willing to perform all study procedures.
  6. Ability to provide written consent signed by the subject

Exclusion Criteria:
  1. Any significant neurological condition or disorder (e.g., seizure disorder, epilepsy, brain tumors, stroke, etc.) that could cause cognitive deterioration other than suspected MCI.
  2. Any medical condition or disorder that could produce cognitive deterioration (i.e., renal, respiratory, cardiac, and hepatic disease, diabetes mellitus, endocrine, metabolic or hematological disturbances) unless well controlled for at least 3 months.
  3. Clinically significant abnormal serum TSH and/or B-12 and/or folic acid levels below the normal range.
  4. History of any infective or inflammatory brain disease including viral, fungal or syphilitic etiologies.
  5. Head trauma or injury immediately preceding cognitive deterioration, unless over 2 years have passed since full cognitive and functional recovery.
  6. Depression at screening as assessed by Geriatric Depression Scale-short version (score =5)
  7. Current suicidality at screening by Columbia Suicidality Severity Rating Scale.
  8. Dementia by DSM-IV criteria.
  9. Concomitant use of medications with potent psychotropic properties (e.g. antipsychotics, ADHD treatments, lithium carbonate, anti-epileptic drugs such as Gabapentin). Sedating antihistamines are allowed if administered last dose is administered at least 12 hours before cognitive testing. Usage of prescription or nonprescription antidepressant agents, lipid lowering medications, and anti-hypertensive medications with a stable dosage for more than 2 months prior study entry is permitted.
  10. Concomitant use of any medications approved for the symptomatic treatment of dementia due to AD (e.g., NMDA, acetyl choline esterase inhibitors)
  11. Use within 3 weeks prior to study entry of any medications with any anti-cholinergic effect (e.g. Atropine, Scopolamine, Tolterodine, Hyoscyamine, Biperiden, Benzatropine, Trihexyphenidyl, Oxybutynin).
  12. Use within 4 weeks prior to the study entry of dietary supplements containing DHA, EPA, Phosphatidylserine, Phosphatidylcholine (e.g. Krill oil, Lecithin), or alpha-glycerphosphocholine (GPC).
  13. Use within 4 weeks prior to the study entry of medical foods indicated for cognitive or memory impairment [e.g. Axona, Cerefolin, CerefolinNAC, Souvenaid].
  14. Concomitant use of any supplements containing ingredients with nootropic or vasodilator properties (e.g., Ginkgo Biloba, Vinpocetine, Piracetam, high energy supplements).
  15. Use of an investigational drug within the last 30 days.
  16. Allergic reaction or sensitivity to marine products (fish/seafood) and/or soy.
  17. Any known condition which in the opinion of the investigator may be possibly causing cognitive impairment other than AD (mania, alcohol or substance abuse, mental retardation, bipolar disorder, panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, psychotic disorder, major psychiatric disorder preceding dementia onset or affecting brain function, major surgery ) and/or limits the successful trial completion

Contact

Colleen Figueroa
University of South Florida - USF Health Psychiatry Center
3515 E Fletcher Ave
Tampa, FL 33613
Phone: (813) 974-9104

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.